Schizophrenia: From dopaminergic to glutamatergic interventions

Current Opinion in Pharmacology

Volumn 14, Issue 1, 2014, Pages 97-102

  Laruelle, Marc ^a  

^a UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID;

ARTICLE; BRAIN FUNCTION; BRAIN REGION; CENTRAL NERVOUS SYSTEM; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; GLUTAMATERGIC SYSTEM; GLUTAMATERGIC TRANSMISSION; MOLECULAR INTERACTION; NEUROIMAGING; NEUROTRANSMISSION; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANIMALS; CORPUS STRIATUM; DOPAMINE; GLUTAMIC ACID; HUMANS; PREFRONTAL CORTEX; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84893831668     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2014.01.001     Document Type: Review

References (74)

1. T.R. Insel Rethinking schizophrenia Nature 468 2010 188 193
2. B. Angrist, and D.P. van Kammen CNS stimulants as a tool in the study of schizophrenia Trends Neurosci 7 1984 388 390 (Pubitemid 14010235)
3. M.B. Knable, and D.R. Weinberger Dopamine, the prefrontal cortex and schizophrenia J Psychopharmacol 11 1997 123 131 (Pubitemid 27252643)
4. H.J. Sørensen, E.L. Mortensen, J. Schiffman, J.M. Reinisch, J. Maeda, and S.A. Mednick Early developmental milestones and risk of schizophrenia: a 45-year follow-up of the Copenhagen Perinatal Cohort Schizophr Res 118 2010 41 47
5. K.A. Woodberry, A.J. Giuliano, and L.J. Seidman Premorbid IQ in schizophrenia: a meta-analytic review Am J Psychiatry 165 2008 579 587 (Pubitemid 351705334)
6. A. Reichenberg, A. Caspi, H. Harrington, R. Houts, R.S.E. Keefe, R.M. Murray, R. Richie Poulton, and T.E. Moffitt Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study Am J Psychiatry 167 2010 160 169
7. B.L. Thompson, and P. Levitt Now you see it, now you don't - closing in on allostasis and developmental basis of psychiatric disorders Neuron 65 2010 437 439
8. I. Creese, D.R. Burt, and S.H. Snyder Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs Science 19 1976 481 483
9. J.A. Lieberman, J.M. Kane, and J. Alvir Provocative tests with psychostimulant drugs in schizophrenia Psychopharmacology 91 1987 415 433 (Pubitemid 17038204)
10. P. Seeman, and T. Lee Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons Science 188 1975 1217 1219
11. P.S. Goldman-Rakic, E.C. Muly III, and G.V. Williams D(1) receptors in prefrontal cells and circuits Brain Res Brain Res Rev 31 2000 295 301
12. K.L. Davis, R.S. Kahn, G. Ko, and M. Davidson Dopamine in schizophrenia: a review and reconceptualization Am J Psychiatry 148 1991 1474 1486
13. D.R. Weinberger Implications of the normal brain development for the pathogenesis of schizophrenia Arch Gen Psychiatry 44 1987 660 669 (Pubitemid 17099795)
14. J.W. Olney, and N.B. Farber Glutamate receptor dysfunction and schizophrenia Arch Gen Psychiatry 52 1995 998 1007
15. D.C. Javitt, and S.R. Zukin Recent advances in the phencyclidine model of schizophrenia Am J Psychiatry 148 1991 1301 1308
16. C.A. Tamminga, H.H. Holcomb, X.M. Gao, and A.C. Lahti Glutamate pharmacology and the treatment of schizophrenia: current status and future directions Int Clin Psychopharmacology 3 1995 29 37 (Pubitemid 26054878)
17. D.C. Goff, and J.T. Coyle The emerging role of glutamate in the pathophysiology and treatment of schizophrenia Am J Psychiatry 158 2001 1367 1377 (Pubitemid 32847232)
18. J.D. Jentsch, and R.H. Roth The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia Neuropsychopharmacology 20 1999 201 225 (Pubitemid 29067401)
19. D.W. Miller, and E.D. Abercrombie Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats Brain Res Bull 40 1996 57 62 (Pubitemid 26129650)
20. L.S. Kegeles, A. Abi-Dargham, Y. Zea-Ponce, J. Rodenhiser-Hill, J.J. Mann, R.L. Van Heertum, T.B. Cooper, A. Carlsson, and M. Laruelle Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia Biol Psychiatry 48 2000 627 640
21. M. Laruelle, R.N. Iyer, M.S. Al-Tikriti, Y. Zea-Ponce, R. Malison, S.S. Zoghbi, R.M. Baldwin, H.F. Kung, D.S. Charney, P.B. Hoffer, R.B. Innis, and C.W. Bradberry Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates Synapse 25 1997 1 14 (Pubitemid 27014356)
22. A. Breier, T.P. Su, R. Saunders, R.E. Carson, B.S. Kolachana, A. deBartolomeis, D.R. Weinberger, N. Weisenfeld, A.K. Malhotra, W.C. Eckelman, and D. Pickar Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method Proc Natl Acad Sci U S A 94 1997 2569 2574 (Pubitemid 27136916)
23. 123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans Synapse 31 1999 302 308 (Pubitemid 29070292)
24. P. Piccini, N. Pavese, and D.J. Brooks Endogenous dopamine release after pharmacological challenges in Parkinson's disease Ann Neurol 53 2003 647 653 (Pubitemid 36529439)
25. V.L. Villemagne, D.F. Wong, F. Yokoi, M. Stephane, K.C. Rice, D. Matecka, D.J. Clough, R.F. Dannals, and R.B. Rothman GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [(11)C]raclopride continuous infusion PET scans Synapse 33 1999 268 273 (Pubitemid 29381933)
26. M. Laruelle, A. Abi-Dargham, C.H. van Dyck, R. Gil, C.D. De Souza, J. Erdos, E. McCance, W. Rosenblatt, C. Fingado, S.S. Zoghbi, R.M. Baldwin, J.P. Seibyl, J.H. Krystal, D.S. Charney, and R.B. Innis Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects Proc Natl Acad Sci U S A 93 1996 9235 9240
27. A. Abi-Dargham, R. Gil, J. Krystal, R.M. Baldwin, J.P. Seibyl, M. Bowers, C.H. van Dyck, D.S. Charney, R.B. Innis, and M. Laruelle Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort Am J Psychiatry 155 1998 761 767 (Pubitemid 28252654)
28. M. Laruelle, A. Abi-Dargham, R. Gil, L. Kegeles, and R. Innis Increased dopamine transmission in schizophrenia: relationship to illness phases Biol Psychiatry 46 1999 56 72 (Pubitemid 29296818)
29. O.D. Howes, A.J. Montgomery, M.C. Asselin, R.M. Murray, I. Valli, P. Tabraham, E. Bramon-Bosch, L. Valmaggia, L. Johns, M. Broome, P.K. McGuire, and P.M. Grasby Elevated striatal dopamine function linked to prodromal signs of schizophrenia Arch Gen Psychiatry 66 2009 13 20
30. R. Narendran, N.S. Mason, M.A. May, C.M. Chen, S. Kendro, K. Ridler, E.A. Rabiner, M. Laruelle, C.A. Mathis, and W.G. Frankle Positron emission tomography imaging of dopamine D2 receptors in the human cortex with [(1)(1)C]FLB 457: reproducibility studies Synapse 65 2010 35 40
31. J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, J.D. Bremner, G.R. Heninger, M. Bowers Jr., and D.S. Charney Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch Gen Psychiatry 51 1994 199 214 (Pubitemid 24081509)
32. A.C. Lahti, B. Koffel, D. LaPorte, and C.A. Tamminga Subanesthetic doses of ketamine stimulate psychosis in schizophrenia Neuropsychopharmacology 13 1995 9 19
33. L.S. Kegeles, A. Abi-Dargham, W.G. Frankle, R. Gil, T.B. Cooper, M. Slifstein, D.R. Hwang, Y. Huang, S.N. Haber, and M. Laruelle Increased synaptic dopamine function in associative regions of the striatum in schizophrenia Arch Gen Psychiatry 67 2010 231 239
34. J. Stevens An anatomy of schizophrenia? Arch Gen Psychiatry 29 1973 177 189
35. T.I. Lidsky Reevaluation of the mesolimbic hypothesis of antipsychotic drug action Schizophr Bull 21 1995 67 74
36. D.R. Weinberger, K.F. Berman, and T.N. Chase Mesocortical dopaminergic function and human cognition Ann N Y Acad Sci 537 1988 330 338 (Pubitemid 19029555)
37. R.S. Kahn, P.D. Harvey, M. Davidson, R.S. Keefe, S. Apter, J.M. Neale, R.C. Mohs, and K.L. Davis Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function Schizophr Res 11 1994 217 224 (Pubitemid 24063741)
38. M. Akil, J.N. Pierri, R.E. Whitehead, C.L. Edgar, C. Mohila, A.R. Sampson, and D.A. Lewis Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects Am J Psychiatry 156 1999 1580 1589 (Pubitemid 29459991)
39. A. Abi-Dargham, O. Mawlawi, I. Lombardo, R. Gil, D. Martinez, Y. Huang, D.R. Hwang, J. Keilp, L. Kochan, R. Van Heertum, J.M. Gorman, and M. Laruelle Prefrontal dopamine D1 receptors and working memory in schizophrenia J Neurosci 22 2002 3708 3719 (Pubitemid 37465776)
40. A. Abi-Dargham, X. Xu, J.L. Thompson, R. Gil, L.S. Kegeles, N. Urban, R. Narendran, D.R. Hwang, M. Laruelle, and M. Slifstein Increased prefrontal cortical D(1) receptors in drug naive patients with schizophrenia: a PET study with [(1)(1)C]NNC112 J Psychopharmacol 26 2012 794 805
41. B.W. Adams, C.W. Bradberry, and B. Moghaddam NMDA antagonist effects on striatal dopamine release: microdialysis studies in awake monkeys Synapse 43 2002 12 18 (Pubitemid 33115663)
42. R. Narendran, W.G. Frankle, N.S. Mason, E.A. Rabiner, R.N. Gunn, G.E. Searle, S. Vora, M. Litschge, S. Kendro, T.B. Cooper, C.A. Mathis, and M. Laruelle Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: a comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride Synapse 63 2009 447 461
43. D.C. Javitt, I. Zylberman, S.R. Zukin, U. Heresco-Levy, and J.P. Lindenmayer Amelioration of negative symptoms in schizophrenia by glycine Am J Psychiatry 151 1994 1234 1236 (Pubitemid 24240973)
44. D.C. Javitt, G. Silipo, A. Cienfuegos, A.M. Shelley, N. Bark, M. Park, J.P. Lindenmayer, R. Suckow, and S.R. Zukin Adjunctive high-dose glycine in the treatment of schizophrenia Int J Neuropsychopharmacol 4 2001 385 391 (Pubitemid 33151682)
45. U. Heresco-Levy, D.C. Javitt, M. Ermilov, C. Mordel, G. Silipo, and M. Lichtenstein Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia Arch Gen Psychiatry 56 1999 29 36 (Pubitemid 29055047)
46. U. Heresco-Levy, D.C. Javitt, M. Ermilov, G. Silipo, and J. Shimoni Double-blind, placebo-controlled, crossover trial of d-cycloserine adjuvant therapy for treatment-resistant schizophrenia Int J Neuropsychopharmcol 1 1998 131 135 (Pubitemid 128538374)
47. U. Heresco-Levy, M. Ermilov, J. Shimoni, B. Shapira, G. Silipo, and D.C. Javitt Placebo-controlled trial of d-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia Am J Psychiatry 159 2002 480 482 (Pubitemid 34184748)
48. D.C. Goff, G. Tsai, J. Levitt, E. Amico, D. Manoach, D.A. Schoenfeld, D.L. Hayden, R. McCarley, and J.T. Coyle A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia Arch Gen Psychiatry 56 1999 21 27 (Pubitemid 29055046)
49. G. Tsai, P. Yang, L.C. Chung, N. Lange, and J.T. Coyle D-serine added to antipsychotics for the treatment of schizophrenia Biol Psychiatry 44 1998 1081 1089 (Pubitemid 28547143)
50. M.J. Millan N-methyl-d-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review Curr Drug Target CNS Neurol Disord 1 2002 191 213
51. D. Umbricht, K. Yoo, E. Youssef, E. Dorflinger, M. Martin-Facklam, A. Bausch, R. Arrowsmith, D. Alberati, S. Marder, and L. Santarelli Glycine Transporter Type 1 (GLYT1) Inhibitor RG1678: positive results of the Proof-of-Concept Study for the Treatment of Negative Symptoms in Schizophrenia Neuropsychophamrmacology 35 2010 S320 S321
52. C.R. Yang, J.K. Seamans, and N. Gorelova Developing a neuronal model for the pathophysiology of schizophrenia based on the nature of electrophysiological actions of dopamine in the prefrontal cortex Neuropsychopharmacology 21 1999 161 194 (Pubitemid 29304579)
53. L.S. Kegeles, D. Martinez, L.D. Kochan, D.R. Hwang, Y. Huang, O. Mawlawi, R.F. Suckow, R.L. Van Heertum, and M. Laruelle NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans Synapse 43 2002 19 29 (Pubitemid 33115664)
54. S. Aalto, J. Hirvonen, J. Kajander, H. Scheinin, K. Nagren, H. Vilkman, L. Gustafsson, E. Syvalahti, and J. Hietala Ketamine does not decrease striatal dopamine D2 receptor binding in man Psychopharmacology (Berl) 164 2002 401 406 (Pubitemid 35435716)
55. M.S. Starr Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease Synapse 19 1995 264 293
56. A.D. Smith, and J.P. Bolam The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones Trends Neurosci 13 1990 259 265 (Pubitemid 20193455)
57. R. Kotter Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum Prog Neurobiol 44 1994 163 196 (Pubitemid 24295989)
58. S.M. Nicola, J. Surmeier, and R.C. Malenka Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens Annu Rev Neurosci 23 2000 185 215 (Pubitemid 30350042)
59. C. Cepeda, and M.S. Levine Dopamine and N-methyl-d-aspartate receptor interactions in the neostriatum Dev Neurosci 20 1998 1 18 (Pubitemid 28132701)
60. C. Konradi, and S. Heckers Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment Pharmacol Ther 97 2003 153 179 (Pubitemid 36138820)
61. M.S. Levine, Z. Li, C. Cepeda, H.C. Cromwell, and K.L. Altemus Neuromodulatory actions of dopamine on synaptically-evoked neostriatal responses in slices Synapse 24 1996 65 78 (Pubitemid 26293169)
62. D. Centonze, B. Picconi, P. Gubellini, G. Bernardi, and P. Calabresi Dopaminergic control of synaptic plasticity in the dorsal striatum Eur J Neurosci 13 2001 1071 1077 (Pubitemid 32275743)
63. P. Karlsson, L. Smith, L. Farde, C. Harnryd, G. Sedvall, and F.A. Wiesel Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients Psychopharmacology (Berl) 121 1995 309 316
64. J. Karle, L. Clemmesen, L. Hansen, M. Andersen, J. Andersen, C. Fensbo, M. Sloth-Nielsen, B.K. Skrumsager, H. Lublin, and J. Gerlach NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia Psychopharmacology (Berl) 121 1995 328 329
65. R. de Beaurepaire, A. Labelle, D. Naber, B.D. Jones, and T.R. Barnes An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states Psychopharmacology (Berl) 121 1995 323 327
66. J.A. Den Boer, H.J. van Megen, W.W. Fleischhacker, J.W. Louwerens, B.R. Slaap, H.G. Westenberg, G.D. Burrows, and O.N. Srivastava Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia Psychopharmacology (Berl) 121 1995 317 322
67. L. Mrzljak, C. Bergson, M. Pappy, R. Huff, R. Levenson, and P.S. Goldman-Rakic Localization of dopamine D4 receptors in GABAergic neurons of the primate brain Nature 381 1996 245 248 (Pubitemid 26148034)
68. J.F. Smiley, A.I. Levey, B.J. Ciliax, and P.S. Goldman-Rakic D1 dopamine receptor immunoreactivity in human and monkey cerebral cortex: predominant and extrasynaptic localization in dendritic spines Proc Natl Acad Sci U S A 91 1994 5720 5724
69. A. Del Arco, and F. Mora Endogenous dopamine potentiates the effects of glutamate on extracellular GABA in the prefrontal cortex of the freely moving rat Brain Res Bull 53 2000 339 345
70. A.C. Grobin, and A.Y. Deutch Dopaminergic regulation of extracellular gamma-aminobutyric acid levels in the prefrontal cortex of the rat J Pharmacol Exp Ther 285 1998 350 357 (Pubitemid 28207606)
71. J.K. Seamans, N. Gorelova, D. Durstewitz, and C.R. Yang Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons J Neurosci 21 2001 3628 3638 (Pubitemid 32422827)
72. N. Gorelova, J.K. Seamans, and C.R. Yang Mechanisms of dopamine activation of fast-spiking interneurons that exert inhibition in rat prefrontal cortex J Neurophysiol 88 2002 3150 3166 (Pubitemid 35448698)
73. J.K. Seamans, D. Durstewitz, B.R. Christie, C.F. Stevens, and T.J. Sejnowski Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons Proc Natl Acad Sci U S A 98 2001 301 306 (Pubitemid 32095904)
74. A.A. Fienberg, N. Hiroi, P.G. Mermelstein, W. Song, G.L. Snyder, A. Nishi, A. Cheramy, J.P. O'Callaghan, D.B. Miller, D.G. Cole, R. Corbett, C.N. Haile, D.C. Cooper, S.P. Onn, A.A. Grace, C.C. Ouimet, F.J. White, S.E. Hyman, D.J. Surmeier, J. Girault, E.J. Nestler, and P. Greengard DARPP-32: regulator of the efficacy of dopaminergic neurotransmission Science 281 1998 838 842 (Pubitemid 28376047)